Skip to content

ACCA Strategic Professional · Advanced Performance Management · Non-financial performance measurement

Hollis Pharma is judged by its board on short-term earnings per share. Its research division has a pipeline of drugs with uncertain but potentially very large future cash flows, and R&D is expensed as incurred in management accounts. Which combination of limitations of financial measures is most relevant to assessing this division?

Short-term EPS is backward-looking and does not capture intangible value such as a drug pipeline. Because R&D is expensed, cutting it lifts current earnings while destroying future value. Non-financial indicators such as pipeline progress and innovation measures are needed to supplement the financial measures.

  1. AFinancial measures ignore intangible value drivers and encourage cutting R&D to meet short-term targets, and they are backward-lookingCorrect
  2. BFinancial measures are too forward-looking and hence speculative for R&D
  3. CFinancial measures fail only because they are compared with a budget
  4. DFinancial measures cannot be audited, so the pipeline value is unreliable

Explanation

Expensing R&D reduces current EPS while the value created is intangible and appears later. This gives an incentive to cut R&D and means reported figures are historic and miss innovation capability. Financial measures are not forward-looking, so the second option is the opposite of the truth.

Did you get it right without looking?

One question tells you little. A timed set on Non-financial performance measurement shows your real accuracy, how long you take and where you lose marks.

More Non-financial performance measurement questions